orano oranomed

INTERNATIONAL STARTUP CALL

Accelerating development of targeted cancer treatments

APPLY BEFORE DECEMBER 6th

POWERED BY hello tomorrow




Identify solutions to test in silico the affinity between tumor targets and targeting molecules in order to pre-select them for in vivo testing

Recent progress in artificial intelligence has allowed the development of tools that predict the 3D conformation of molecules. The affinity between the targeting molecule and the tumor target is an essential criterion of efficacy, which depends to a large extent on the 3D configuration of both of the molecules.

Affinity tests are currently performed in vitro and then in vivo, which is very time-consuming and expensive.

How targeted radiotherapy works on cancer cells



TODAY

ORANO MED
DEVELOPS INTERNAL VECTORIZED RADIOTHERAPY TREATMENTS

TOMORROW

ORANO MED
SEEKS TO ACCELERATE THE DEVELOPMENT OF NEW TREATMENTS TO FIGHT CANCERS THAT HAVE REACHED A THERAPEUTIC DEAD-END

orano oranomed POWERED BY hello tomorrow

Benefit from...

REAL DATA

Test your solution
and validate it on real
in vivo data

EXPERT NETWORK

Connect and get visibility
with biotech experts
(board members) &
Orano Med's ecosystem

PARTNERSHIP

If testing your solution on real
data is a success, opportunity
to develop a co-financed POC
with Orano Med's team

UNIQUE EXPERIENCE

Best startups will be offered
a Hello Tomorrow Global Summit pass
with travel expenses covered by Orano*

**In accordance with Orano's travel policy*

APPLY NOW

orano oranomed POWERED BY hello tomorrow

Timeline

NOVEMBER 8TH

AMA webinar!
Orano Med and Hello Tomorrow will discuss Challenge topics, eligibility criteria, and prizes. Questions welcome!

OCTOBER 10TH

Application opened
Fill in your application online

DECEMBER 6TH

Application closed
Submit your online application before December 6th , at midnight CEST

JANUARY - FEBRUARY

Alignment calls
Orano Med and selected startups to align on goals and expectations

MARCH 9 - 10TH

Final Event
Meet the Orano Med team at the Global Summit

FROM MARCH

Testing phase
Experimental data provided to validate models and beginning of the collaboration with Orano Med

APPLY NOW

orano oranomed POWERED BY hello tomorrow

Targeted Alpha Therapy: a powerful way to treat cancer

OUR AMBITION

Orano Med's ambition is to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (^{212}Pb), a rare alpha-emitting radioisotope and one of the most potent therapeutic payloads against cancer cells. Our approach, known as Targeted Alpha Therapy (TAT), has the potential to bring significant benefits where conventional therapies have failed to treat patients.

OUR STRATEGY

Orano Med's strategy focuses on developing a robust pipeline of ^{212}Pb-based therapies and securing a robust supply chain of ^{212}Pb.

We focus our activities on areas of high unmet needs where ^{212}Pb-labeled compounds could make a difference, and we are equipped since 2016 with a preclinical facility dedicated to accelerate clinical translation of our molecules.

Orano Med wants to reach out to the world's most creative and innovative minds.


Do you have what it takes?

orano oranomed POWERED BY hello tomorrow

ORANO MED IN A NUTSHELL

- Early 2000s, AREVA (now Orano) sought to develop the use of materials derived from its core nuclear energy activities
- Nuclear medicine and Targeted Alpha Therapy quickly appeared very promising
- AREVA Med created in 2009 (Renamed Orano Med in 2018) to develop novel therapies against cancer
- World first clinical trial with ^{212}Pb performed between 2012 and 2014
- Now more than 80 employees in France and the USA


Orano is an **ecosystem of opportunities**



OUR FACILITIES

Two facilities for preclinical and clinical development of ^{212}Pb therapies in France (in partnership with Roche) and in the USA.

orano oranomed



APPLY NOW